COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS - ARROWHEAD PHARMACEUTICALS IN ownership

ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 254 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.2%.

Quarter-by-quarter ownership
COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS ownership history of ARROWHEAD PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$583,267
-68.3%
21,707
-58.0%
0.01%
-64.3%
Q2 2023$1,842,695
+48.7%
51,674
+5.9%
0.01%
+27.3%
Q1 2023$1,239,088
+64068.2%
48,783
+2.4%
0.01%
-31.2%
Q4 2022$1,931
-99.9%
47,617
+13.5%
0.02%
+14.3%
Q3 2022$1,387,000
-5.9%
41,967
+0.3%
0.01%
-12.5%
Q2 2022$1,474,000
-17.1%
41,859
+8.3%
0.02%
-11.1%
Q1 2022$1,778,000
-22.4%
38,650
+11.8%
0.02%
-25.0%
Q4 2021$2,292,000
+6.6%
34,567
+0.4%
0.02%
-4.0%
Q3 2021$2,150,000
-25.1%
34,444
-0.7%
0.02%
-21.9%
Q2 2021$2,872,000
+25.1%
34,675
+0.1%
0.03%
+14.3%
Q1 2021$2,296,000
-12.8%
34,626
+0.9%
0.03%
-24.3%
Q4 2020$2,633,000
+86.5%
34,314
+4.7%
0.04%
+32.1%
Q3 2020$1,412,000
+51.8%
32,785
+52.3%
0.03%
+64.7%
Q2 2020$930,000
+37.2%
21,531
-8.6%
0.02%
+13.3%
Q1 2020$678,000
-39.5%
23,551
+33.4%
0.02%
-25.0%
Q4 2019$1,120,000
+22.9%
17,657
-45.4%
0.02%
+25.0%
Q3 2019$911,000
+5.8%
32,325
-0.5%
0.02%
+6.7%
Q2 2019$861,00032,4730.02%
Other shareholders
ARROWHEAD PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
WESTERN FINANCIAL Corp 820,346$62,945,00041.38%
Johnson & Johnson Innovation - JJDC, Inc. 3,260,869$250,206,00032.27%
Aquilo Capital Management, LLC 365,926$28,078,0005.84%
L1 Capital Pty Ltd 298,687$23,127,0004.32%
First Light Asset Management, LLC 704,449$54,052,0004.00%
ACUTA CAPITAL PARTNERS, LLC 139,000$10,665,0002.90%
Evolutionary Tree Capital Management, LLC 48,265$3,703,0002.82%
Parkman Healthcare Partners LLC 127,171$9,758,0002.50%
Capital Impact Advisors, LLC 88,183$6,766,0001.66%
Tri Locum Partners LP 56,003$4,297,0001.56%
View complete list of ARROWHEAD PHARMACEUTICALS IN shareholders